A drug already on the market for osteoporosis has blocked spinal damage in a new study, raising hopes for a future treatment for back pain. Researchers in the United Kingdom found that the drug prevented mineral buildup and spinal fusion in zebrafish with a faulty collagen gene, a condition that mirrors human disc disease.
The discovery emerged from a study at the Universities of Edinburgh and Bristol, published August 6, 2026. The team bred zebrafish lacking a functional copy of a gene linked to collagen IX, a protein that helps hold spinal discs together. As the fish aged, their vertebrae fused and mineral deposits hardened the tissue between bones, closely resembling intervertebral disc degeneration (IVDD) in people.
A Chain Reaction of Damage
The researchers found that mineralization did not happen right away. First, a supportive scaffold layer inside the developing spine began to break down. Only after this early structural damage did minerals start to accumulate. This sequence suggests that genetic changes set off a chain reaction, leading to the spine's natural shock absorbers hardening and deteriorating.
By analyzing gene activity in the fish, the team identified several disrupted processes. Fat metabolism was impaired, the mTOR growth pathway was altered, and there were changes in phosphate control and vitamin A signaling. Each of these has been linked to abnormal mineral accumulation in other contexts.
An Existing Drug Shows Promise
The researchers tested several approaches to reduce the damage. A bisphosphonate, a type of bone-protecting medication already used for osteoporosis, prevented minerals from accumulating in the zebrafish spine. Targeting fat metabolism also reduced spinal fusion. These results point to multiple potential targets for future therapies.
Local researchers and clinicians care because back pain is a massive global burden. Most people experience it at some point, and IVDD is a leading cause. Currently, no medications can halt or reverse disc degeneration. Surgery remains the only long-term treatment. The study suggests that zebrafish could serve as a useful model for testing new drugs, and that existing medications might be repurposed for back pain.
The findings are early, but they offer a concrete biological pathway from genetic risk to disc damage. The next step is to see whether these mechanisms hold in mammals and eventually in humans. For now, the study provides a clear direction: a drug already proven safe in people may one day help protect the spine.
